Penumbra stock has November 4 earnings date with USD 401.41 million forecast

Published on 10/17/2026 at 20:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Analysts expect USD 1.20 earnings per share in the third quarter. Penumbra stock costs USD 320.86 on October 16, 2026, down 0.11 percent versus the prior close.

Reporting date and valuation

MarketBeat lists November 4, 2026 for Penumbra's third-quarter report and a USD 401.41 million revenue estimate.
Analysts expect USD 1.20 earnings per share for the third quarter.
Penumbra stock last traded at USD 320.86 on October 16, 2026 at 4:00 p.m. ET, down 0.11 percent versus the prior close.
Penumbra had a USD 12.6 billion market capitalization and a 78.84 price-to-earnings ratio as of October 16, 2026.

PEN, US70975L1070, Illustration mit AI erstellt.

Penumbra, Inc. (ISIN US70975L1070) has a scheduled third-quarter earnings date of November 4, 2026, with analysts expecting USD 401.41 million in revenue. MarketBeat identifies the date as an estimate and lists a conference call after the market close.

Third-quarter expectations include USD 1.20

The same MarketBeat page lists consensus earnings per share of USD 1.20 for the third quarter, compared with USD 0.97 in the year-ago quarter. The revenue estimate of USD 401.41 million compares with USD 354.69 million a year earlier, implying growth of 13.17 percent on the source figures.

Penumbra's latest reported quarter ended June 30, 2026. The company reported USD 390.05 million in revenue and USD 0.88 diluted earnings per share, while the prior-year quarter delivered USD 0.86 earnings per share, according to MarketBeat. The revenue comparison was positive, but the earnings figure missed the cited USD 1.16 consensus estimate.

Stock sits inside its yearly range

On the NYSE, Penumbra last traded at USD 320.86 on October 16, 2026 at 4:00 p.m. ET, down 0.11 percent from the prior close of October 15, 2026. The USD 221.26 to USD 362.41 52-week range puts the latest price 11.47 percent below the high and 45.00 percent above the low.

The finance profile places Penumbra in health care medical devices. Its business covers thrombectomy, embolization, access systems and neurovascular products, while the investor-relations page describes operations serving providers in more than 100 countries.

Valuation remains central

Penumbra's market capitalization was USD 12.6 billion as of October 16, 2026, with a price-to-earnings ratio of 78.84. The company paid no trailing dividend in the quoted figures. The November 4 report is the next dated corporate event identified for the stock.

Comparison with peers

Penumbra (NYSE, USD): minus 0.11 percent, P/E 78.84, market capitalization USD 12.6 billion

Boston Scientific (NYSE, USD): plus 0.57 percent, P/E 18.04, market capitalization USD 64.3 billion

Stryker (NYSE, USD): plus 0.49 percent, P/E 30.53, market capitalization USD 113.0 billion

Price and reporting date

The next report date gives investors a clear calendar marker, while the latest valuation remains higher than the peer ratios shown above. Penumbra's latest trading price was USD 320.86 on the NYSE on October 16, 2026 at 4:00 p.m. ET.